ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Elucidating Tumorigenesis Mechanisms and Assessing Immunotherapeutic Efficacy in Patient-Derived Medulloblastoma Organoid Models.International journal of biological sciences · 2026Article
- Insights on the differences between two‑ and three‑dimensional culture systems in tumor models (Review).International journal of molecular medicine · 2025Review
- Patient-derived organoids in hepatobiliary pancreatic cancer research: Their uses and limitations.World journal of gastroenterology · 2025Article
- Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy.International journal of molecular sciences · 2025Review
- Organoid in droplet: Production of uniform pancreatic cancer organoids from single cells.Materials today. Bio · 2025Article
- Pancreatic 3D Organoids and Microfluidic Systems-Applicability and Utilization in Surgery: A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Landscape of human organoids: Ideal model in clinics and research.Innovation (Cambridge (Mass.)) · 2024Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.